Paper39309477
Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma?
Fiocchi A and 8 others. J Asthma Allergy, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma? Papers, record 39309477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39309477
- Disease
- asthma423 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00079937 | Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT00252135 | A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT01922037 | A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) | Derived from the trial | Yes | ClinicalTrials.gov |
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36119657 | Managing food allergy: GA2LEN guideline 2022. | World Allergy Organ J | 2022 | https://conductscience.org/library/papers/36119657 | PubMed |
| 2 | 38407394 | Omalizumab for the Treatment of Multiple Food Allergies. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38407394 | PubMed |
| 3 | 33465457 | No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities. | Ann Allergy Asthma Immunol | 2021 | https://conductscience.org/library/papers/33465457 | PubMed |
| 4 | 11496232 | Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. | J Allergy Clin Immunol | 2001 | https://conductscience.org/library/papers/11496232 | PubMed |
| 5 | 30797778 | Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study. | J Allergy Clin Immunol Pract | 2019 | https://conductscience.org/library/papers/30797778 | PubMed |
| 6 | 37779534 | Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH). | J Allergy Clin Immunol Glob | 2022 | https://conductscience.org/library/papers/37779534 | PubMed |
| 7 | 25923451 | Perceived food hypersensitivity relates to poor asthma control and quality of life in young non-atopic asthmatics. | PLoS One | 2015 | https://conductscience.org/library/papers/25923451 | PubMed |
| 8 | 18380635 | Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. | Value Health | 2008 | https://conductscience.org/library/papers/18380635 | PubMed |
| 9 | 11529281 | The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. | Eur Respir J | 2001 | https://conductscience.org/library/papers/11529281 | PubMed |
| 10 | 19788018 | Baseline characteristics of patients enrolled in EXCELS: a cohort study. | Ann Allergy Asthma Immunol | 2009 | https://conductscience.org/library/papers/19788018 | PubMed |
| 11 | 19910033 | Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. | J Allergy Clin Immunol | 2009 | https://conductscience.org/library/papers/19910033 | PubMed |
| 12 | 17469157 | Food allergy and asthma morbidity in children. | Pediatr Pulmonol | 2007 | https://conductscience.org/library/papers/17469157 | PubMed |
| 13 | 34588784 | Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study. | J Asthma Allergy | 2021 | https://conductscience.org/library/papers/34588784 | PubMed |
| 14 | 11150011 | Fatalities due to anaphylactic reactions to foods. | J Allergy Clin Immunol | 2001 | https://conductscience.org/library/papers/11150011 | PubMed |
| 15 | 26215729 | Pathogenesis of IgE-mediated food allergy. | Clin Exp Allergy | 2015 | https://conductscience.org/library/papers/26215729 | PubMed |
| 16 | 35539896 | World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update - XIV - Recommendations on CMA immunotherapy. | World Allergy Organ J | 2022 | https://conductscience.org/library/papers/35539896 | PubMed |
| 17 | 14713908 | Development of the asthma control test: a survey for assessing asthma control. | J Allergy Clin Immunol | 2004 | https://conductscience.org/library/papers/14713908 | PubMed |
| 18 | 36681581 | Might biologics serve to interrupt the atopic march? | J Allergy Clin Immunol | 2023 | https://conductscience.org/library/papers/36681581 | PubMed |
| 19 | 24058900 | Food allergy and increased asthma morbidity in a School-based Inner-City Asthma Study. | J Allergy Clin Immunol Pract | 2013 | https://conductscience.org/library/papers/24058900 | PubMed |
| 20 | 1549827 | Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. | Thorax | 1992 | https://conductscience.org/library/papers/1549827 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41208997 | Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults. | Front Immunol | 2025 | https://conductscience.org/library/papers/41208997 | PubMed |
| 40497014 | Health care resource utilization of patients with asthma and food allergy initiating omalizumab. | J Allergy Clin Immunol Glob | 2025 | https://conductscience.org/library/papers/40497014 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IGHE | 3497 | PubTator's text mining | https://conductscience.org/library/genes/3497 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| OMALIZUMAB | CHEMBL1201589 | Derived from the trial | 2 | https://conductscience.org/library/drugs/CHEMBL1201589 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39309477
GET https://conductscience.org/api/papers/v1/39309477/references?page=2